Literature DB >> 3493905

Effect of miocamycin on theophylline kinetics in children.

N Principi, J Onorato, M G Giuliani, A Vigano.   

Abstract

The interaction between a new macrolide antibiotic, miocamycin, and theophylline was evaluated in a single cross-over study in 5 asthmatic children. Each patient received a single dose of theophylline (4.3 mg/kg) delivered in 15 min using a constant-rate infusion pump, immediately before and after a 10 day course of miocamycin 17.5 mg/kg b.d. The pharmacokinetics of theophylline were calculated for each phase of the study. The elimination rate constant (3.92 vs 3.74 h-1), the mean total body clearance (1.71 vs 1.8 ml X min X kg-1) and the mean apparent volume of distribution (0.57 vs 0.581 X kg-1) did not differ. The result can be explained by the inability of the antibiotic to form inactive cytochrome P-450 metabolite complexes which can interfere with the metabolism of theophylline. Thus, miocamycin can safely be administered to asthmatic children requiring theophylline treatment, when they have an infection due to susceptible pathogens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493905     DOI: 10.1007/BF00541298

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Pharmacokinetics of theophylline in children with asthma.

Authors:  E F Ellis; R Koysooko; G Levy
Journal:  Pediatrics       Date:  1976-10       Impact factor: 7.124

2.  Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration.

Authors:  D Pessayre; M Konstantinova-Mitcheva; V Descatoire; B Cobert; J C Wandscheer; R Level; G Feldmann; D Mansuy; J P Benhamou
Journal:  Biochem Pharmacol       Date:  1981-03-15       Impact factor: 5.858

3.  [Influence of a new macrolide, midecamycin on theophylline pharmacokinetics (author's transl)].

Authors:  J Lavarenne; M Paire; O Talon
Journal:  Therapie       Date:  1981 Jul-Aug       Impact factor: 2.070

4.  Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450.

Authors:  G Danan; V Descatoire; D Pessayre
Journal:  J Pharmacol Exp Ther       Date:  1981-08       Impact factor: 4.030

5.  Interaction of theophylline with erythromycin base in a patient with seizure activity.

Authors:  R A Parish; N J Haulman; R M Burns
Journal:  Pediatrics       Date:  1983-12       Impact factor: 7.124

6.  Depression of theophylline elimination by erythromycin.

Authors:  K W Renton; J D Gray; O R Hung
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

7.  The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice.

Authors:  F W Henderson; W A Clyde; A M Collier; F W Denny; R J Senior; C I Sheaffer; W G Conley; R M Christian
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

8.  Lack of clinically important interaction between erythromycin and theophylline.

Authors:  R Hildebrandt; U Gundert-Remy; H Möller; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Treatment of acute pneumonia in infants and children.

Authors:  S S Long
Journal:  Pediatr Clin North Am       Date:  1983-04       Impact factor: 3.278

10.  Effect of erythromycin base on theophylline kinetics.

Authors:  B J Zarowitz; S J Szefler; G M Lasezkay
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

View more
  8 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Lack of effect of ponsinomycin on the plasma pharmacokinetics of theophylline.

Authors:  W Couet; I Ingrand; B Reigner; J Girault; J Bizouard; J B Fourtillan
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Effect of ponsinomycin on cyclosporin pharmacokinetics.

Authors:  W Couet; B Istin; P Seniuta; D Morel; L Potaux; J B Fourtillan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

5.  Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers.

Authors:  W Couet; B Istin; J P Decourt; I Ingrand; J Girault; J B Fourtillan
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 6.  Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  S M Holliday; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 7.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 8.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.